Literature DB >> 18254958

Transcriptomic dissection of tongue squamous cell carcinoma.

Hui Ye1, Tianwei Yu, Stephane Temam, Barry L Ziober, Jianguang Wang, Joel L Schwartz, Li Mao, David T Wong, Xiaofeng Zhou.   

Abstract

BACKGROUND: The head and neck/oral squamous cell carcinoma (HNOSCC) is a diverse group of cancers, which develop from many different anatomic sites and are associated with different risk factors and genetic characteristics. The oral tongue squamous cell carcinoma (OTSCC) is one of the most common types of HNOSCC. It is significantly more aggressive than other forms of HNOSCC, in terms of local invasion and spread. In this study, we aim to identify specific transcriptomic signatures that associated with OTSCC.
RESULTS: Genome-wide transcriptomic profiles were obtained for 53 primary OTSCCs and 22 matching normal tissues. Genes that exhibit statistically significant differences in expression between OTSCCs and normal were identified. These include up-regulated genes (MMP1, MMP10, MMP3, MMP12, PTHLH, INHBA, LAMC2, IL8, KRT17, COL1A2, IFI6, ISG15, PLAU, GREM1, MMP9, IFI44, CXCL1), and down-regulated genes (KRT4, MAL, CRNN, SCEL, CRISP3, SPINK5, CLCA4, ADH1B, P11, TGM3, RHCG, PPP1R3C, CEACAM7, HPGD, CFD, ABCA8, CLU, CYP3A5). The expressional difference of IL8 and MMP9 were further validated by real-time quantitative RT-PCR and immunohistochemistry. The Gene Ontology analysis suggested a number of altered biological processes in OTSCCs, including enhancements in phosphate transport, collagen catabolism, I-kappaB kinase/NF-kappaB signaling cascade, extracellular matrix organization and biogenesis, chemotaxis, as well as suppressions of superoxide release, hydrogen peroxide metabolism, cellular response to hydrogen peroxide, keratinization, and keratinocyte differentiation in OTSCCs.
CONCLUSION: In summary, our study provided a transcriptomic signature for OTSCC that may lead to a diagnosis or screen tool and provide the foundation for further functional validation of these specific candidate genes for OTSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254958      PMCID: PMC2262071          DOI: 10.1186/1471-2164-9-69

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


Background

Head and neck/oral squamous cell carcinoma (HNOSCC) is a complex disease arising in various organs, including oral cavity, tongue, pharynx, and larynx. Tumors from these different sites have distinct clinical presentations and clinical outcomes, and are associated with different risk factors [1] and genetic characteristics [2]. In this study, we focused on the oral tongue squamous cell carcinomas (OTSCC), one of the most common sites for HNOSCCs. The incidence of OTSCC is actually increasing in young and middle age groups [3-5]. OTSCC is significantly more aggressive than other forms of HNOSCCs, with a propensity for rapid local invasion and spread [6]. Cancer cells harbor genetic alterations which are translated into unique expression patterns. These patterns may segregate cancer cells from normal tissue of the same origin and serve as a molecular biomarker. Moreover, expression pattern changes may occur far earlier than clinical disease detection. The identification of such patterns has significant translational values for early detection and diagnosis, as well as for identifying novel therapeutic targets. While several recent studies have attempted to identify expression patterns for HNOSCCs [7-10], to our knowledge, no study has been devoted to identify the unique expression pattern for OTSCC. In this study, we aim to identify the specific transcriptomic/expression patterns that associated with OTSCC.

Results and discussion

Genome-wide gene expression profiles were obtained on 53 OTSCC samples and 22 normal matching samples. Principal Component Analysis (PCA) was performed based on all the probesets utilized in our microarray analysis. Apparent separation between OTSCC and normal groups was observed with a few outliers (Figure 1). Genes showing statistically significant differences in expression level were identified using RMA and a mixed-effects model as described in the Materials and Methods section. A signature gene set that consists of 35 genes was created using stringent statistical criteria (fold change > 4, and FDR values < 0.0001) (Table 1). Comprehensive lists of genes showing statistically significant upregulations (fold change > 2, and FDR values < 0.01) or downregulations in expression in OTSCC were presented in Supplement Table S1 [see additional file 1] and S2 [see additional file 2], respectively.
Figure 1

Principle component analysis. Global gene expression profiles on 53 OTSCC and 22 matching normal samples were obtained as described in Materials and Methods section. Principle Component (PC) analysis was performed based on the expression profiles of samples. The first 3 PCs were plotted. Red: OTSCC, Blue: normal.

Table 1

Signature gene sets for OTSCC

SymbolProbe IDGene NameLocation
Upregulated genes in OTSCC
MMP1204475_atmatrix metalloproteinase 111q22.3
MMP10205680_atmatrix metalloproteinase 1011q22.3
MMP3205828_atmatrix metalloproteinase 311q22.3
MMP12204580_atmatrix metallopeptidase 1211q22.3
PTHLH211756_atparathyroid hormone-like hormone12p12.1-p11.2
INHBA210511_s_atinhibin, beta A7p15-p13
LAMC2202267_atlaminin, gamma 21q25-q31
IL8202859_x_atinterleukin 84q13-q21
KRT17205157_s_atkeratin 1717q12-q21
COL1A2202404_s_atcollagen, type I, alpha 27q22.1
IFI6204415_atinterferon, alpha-inducible protein 61p35
ISG15205483_s_atISG15 ubiquitin-like modifier1p36.33
PLAU205479_s_atplasminogen activator, urokinase10q24
GREM1218468_s_atgremlin 115q13-q15
MMP9203936_s_atmatrix metallopeptidase 920q11.2-q13.1
IFI44214453_s_atinterferon-induced protein 441p31.1
CXCL1204470_atchemokine (C-X-C motif) ligand 14q21
Downregulated genes in OTSCC
KRT4213240_s_atkeratin 412q12-q13
MAL204777_s_atmal, T-cell differentiation protein2cen-q13
CRNN220090_atCornulin1q21
SCEL206884_s_atSciellin13q22
CRISP3207802_atcysteine-rich secretory protein 36p12.3
SPINK5205185_atserine protease inhibitor, Kazal type 55q32
CLCA4220026_atchloride channel, calcium activated, family member 41p31-p22
ADH1B209612_s_at 209613_s_atalcohol dehydrogenase IB (class I), beta polypeptide4q21-q23
P11206605_at26 serine protease12q13.1
TGM3206004_attransglutaminase 320q11.2
RHCG219554_atRhesus blood group, C glycoprotein15q25
PPP1R3C204284_atprotein phosphatase 1, regulatory (inhibitor) subunit 3C10q23-q24
CEACAM7206199_atcarcinoembryonic antigen-related cell adhesion molecule 719q13.2
HPGD203914_x_athydroxyprostaglandin dehydrogenase 15-(NAD)4q34-q35
CFD205382_s_atD component of complement (adipsin)19p13.3
ABCA8204719_atATP-binding cassette, sub-family A (ABC1), member 817q24
CLU222043_atClusterin8p21-p12
CYP3A5214235_atcytochrome P450, family 3, subfamily A, polypeptide 57q21.1

* The complete lists of upregulated and downregulated transcripts in OTSCCs were presented in Supplement Table S1 and S2, respectively.

Principle component analysis. Global gene expression profiles on 53 OTSCC and 22 matching normal samples were obtained as described in Materials and Methods section. Principle Component (PC) analysis was performed based on the expression profiles of samples. The first 3 PCs were plotted. Red: OTSCC, Blue: normal. Signature gene sets for OTSCC * The complete lists of upregulated and downregulated transcripts in OTSCCs were presented in Supplement Table S1 and S2, respectively. In this study, we identified and validated several interesting potential biomarkers for OTSCC diagnosis. One interesting observation is that 5 members of the Matrix Metalloproteinase (MMP) family (MMP1 MMP3, MMP9, MMP10, and MMP12) are among the genes that most significantly upregulated, which may contribute to the aggressive nature of the OTSCC. MMPs are a large family of proteinases which remodel extracellular matrix (ECM) components and play a significant role in tumor development, survival, invasion and metastasis [11-13]. Several members of the MMP family have been considered to be important biomarkers for diagnosis and prognosis as well as potential therapeutic targets for many types of cancers, including HNOSCC [14]. Our recent study suggested that up regulation of the MMP9 gene is associated with advanced OTSCC and has predictive value for the identification of lymph node metastasis [15]. Here, our data further suggested that MMP9 is one of the biomarkers for the detection of OTSCC. We also observed 2 chemokines (IL8 and CXCL1) to be among the most significantly upregulated genes in OTSCC. The increase in the protein and mRNA of IL8 gene has been suggested as a biomarker for the early detection of oral cancer [16,17]. Our data provided independent validation for this biomarker at the disease tissue level, and suggested that the increase of IL8 molecules (mRNA and protein) is due at least in part to the increased expression of gene in the disease tissues. CXCL1, also known as growth-regulated oncogene 1 (Gro-1), is vital for the survival, progression and invasion of several cancer types [18,19], including oral cancer [20]. Our results here further confirmed the importance of CXCL1 in the tumorgenesis of tongue cancer. Other interesting observations include the up-regulation of KRT17 (associated with invasion and proliferation) and down-regulation of KRT4 (which is associated with squamous cell differentiation), suggesting the potentially distinct roles of KRT genes in tongue SCC development and progression. In addition to those identified biomarkers, our results will also serve as a valuable reference data set for future development and validation of biomarkers for detection, diagnosis and prognosis of tongue cancer. To test the utility of this 35-gene signature gene set for classifying OTSCC and normal groups, average linkage hierarchical clustering analysis was performed. As illustrated in Figure 2, our results demonstrated that this 35-gene set provides classification power for OTSCC based on gene expression analyses, which misclassified two cases for each of two groups (a 95% overall accuracy rate).
Figure 2

Classification of OTSCC and matching normal using global gene expression analysis. A signature gene set of 35 genes was created based on RMA analysis of the expression profiles on 53 OTSCC and 22 matching normal samples. Hierarchical clustering was performed based on this signature gene set. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting.

Classification of OTSCC and matching normal using global gene expression analysis. A signature gene set of 35 genes was created based on RMA analysis of the expression profiles on 53 OTSCC and 22 matching normal samples. Hierarchical clustering was performed based on this signature gene set. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting. Our analysis demonstrated that OTSCC can be identified based on the gene expression signature. This finding should provide a foundation for the creation of a specific screen tool for OTSCC. One of the major factors accounting for the poor outcome of OTSCC patients is that a great proportion of oral cancers are diagnosed at advanced stages. Patients diagnosed at an early stage of the disease typically have a better chance for cure and functional outcome. Early detection of tongue cancer lesion will greatly improve patient survival and the quality of life. Current clinical diagnosis and histopathologic examinations are usually based on biopsied material, which requires invasive procedures and surgical techniques. The emerging technology of saliva-based diagnosis may provide an alternative strategy for early diagnosis and screening of the subjects at risk [21]. The markers identified here may be suitable for the saliva-based early diagnosis and screening strategy [17,21]. Additional validation studies will be needed to fully explore this possibility. To gain a better understanding of the underlying molecular biological processes that dictate the observed expressional pattern alterations in OTSCC development, the Gene Ontology analysis was performed. It was carried out using the GOstats package in the Bioconductor [22] and Gene Ontology Consortium database [23], based on the complete list of 365 differentially expressed transcripts (Supplement Table S1 and S2). Among those 365 genes, 306 were mapped to ENTREZ genes. The gene universe in the analysis consists of 13125 transcripts that were mapped to ENTREZ genes. The Gene Ontology analysis suggested a number of altered biological processes in OTSCC. These include enhancement in phosphate transport, collagen catabolism, I-kappaB kinase/NF-kappaB signaling cascade, extracellular matrix organization and biogenesis, chemotaxis, as well as suppression of superoxide release, hydrogen peroxide metabolism, cellular response to hydrogen peroxide, keratinization, keratinocyte differentiation in OTSCCs (Table 2). The complete lists of enhanced and suppressed biological processes, molecular functions and cellular components in OTSCCs were presented in Supplement Table S3 [see additional file 3] and S4 [see additional file 4], respectively.
Table 2

Selected biological processes that altered in OTSCCs *

GO NameGO ID% Change **p-value
Enhanced
Collagen catabolismGO:003057438.92.7 E-09
Positive regulation of chemotaxisGO:005092133.30.0029
Phosphate transportGO:000681721.71.5 E-12
Extracellular matrix organization and biogenesisGO:003019812.90.00089
Positive regulation of I-kappaB kinase/NF-kappaB cascadeGO:00431238.80.00038
Suppressed
Superoxide releaseGO:004255440.00.0015
KeratinizationGO:003142433.31.1 E-05
Hydrogen peroxide metabolismGO:004274325.00.0042
Response to hydrogen peroxideGO:004254222.20.0053
Keratinocyte differentiationGO:003021621.18.0 E-05

* The complete lists of enhanced and suppressed biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCCs were presented in Supplement Table S3 and S4, respectively.

** The percent of genes exhibiting expressional changes among all genes that constitutes a specific GO entity.

Selected biological processes that altered in OTSCCs * * The complete lists of enhanced and suppressed biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCCs were presented in Supplement Table S3 and S4, respectively. ** The percent of genes exhibiting expressional changes among all genes that constitutes a specific GO entity. Among the identified alteration in biological activities in OTSCC, the most significantly enhanced are related to the extracellular matrix remodeling (GO:0030574, GO:0030198), I-kappaB kinase/NF-kappaB cascade (GO:0043123) and chemotaxis (GO:0050921), which are known to be related to tumorgenesis and progression of the cancer. One interesting observation is the enhancement in phosphate transport (GO:0006817) in OTSCC. This may be related directly to the enhanced metabolic activity and energy consumption rate in OTSCCs. It has also been suggested that phosphate can act as a signaling molecule on the extracellular signal-regulated kinase (ERK1/2) [24] and adenylate cyclase/cAMP signaling pathways [25], and ultimately affect cell growth. However, the precise role of enhanced phosphate transport in tumorgenesis is largely unclear. The significantly suppressed biological activities, such as superoxide release (GO:0042554), hydrogen peroxide metabolism (GO:0042743), and response to hydrogen peroxide (GO:0042542) are all appeared to be related to the cellular redox state. The effects of redox state in malignancies are somewhat contradictory. In theory, reducing the oxidative stress may prevent DNA degeneration and therefore prevent the development of cancer. However, doing so may also offer increased growth potential to tumor cells and protect them from excess of reactive oxygen species (ROS), which would otherwise lead to apoptosis or necrosis. At the center of this apparent controversy is superoxide dismutase 2 (SOD2), which has been considered as one of the most important antioxidant enzymes. The role of SODs in carcinogenesis has been widely studied but is still rather ambiguous. While the majority of in vitro studies have reported a protective role of SOD2 against tumor progression in cancer cell lines [26-30], including oral cancer cell lines [31], the in vivo studies indicate more complicated roles. Increased SOD2 levels have been observed from esophageal, gastric, brain astrocytic and colorectal carcinomas, and often associated with metastasis and poor prognosis [32-40]. The status of SOD2 in breast cancer is not clear, with some studies showing an increase [41], while others showing a decrease in SOD2 level [42]. Reduction in SOD2 level has been observed in prostatic carcinomas [43,44]. Our microarray results indicated a significant increase in expression of SOD2 gene (probset: 215223_s_at; fold change = 2.37; p value = 0.00014; and probeset: 216841_s_at; fold change = 2.24; p value = 0.000197) in OTSCC. These findings are in agreement with the recent observation in oral cancer [45]. Additional studies will be needed to fully understand the role(s) of redox state and SOD2 in OTSCC. To visualize the changes in gene expression patterns in relationship with the alteration of biological processes and cellular functions in OTSCC, gene expression heat maps for each identified GO entities were generated based on the microarray results of 53 OTSCC and 22 normal samples (Figure 3). Apparent differences in expression patterns can be observed between OTSCC and normal groups for all the altered GO entities. The summarized statistical values on differential expression for each individual gene of GO:0030574 (collagen catabolism) and GO:0050921 (positive regulation of chemotaxis) are presented in Table 3. The complete expressional analysis for all the altered biological processes identified in Table 2 is presented in Supplement Table S5 [see additional file 5].
Figure 3

Expression values of the genes constitute of the altered biological processes in OTSCC. The altered biological processes in OTSCC were identified by Gene Ontology analysis (Table 2) as described in the Materials and Methods section. The expression values of the genes consisting of the altered biological processes were extracted from the RMA based expression index, and individual heat maps were generated for the identified altered biological processes in OTSCC. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting. To increase the contrast, values lower than the 10th percentile were replaced with the 10th percentile, and values higher than the 95th percentile were replaced with the 95th percentile.

Table 3

Expression values of genes that constitute the collagen catabolism (GO:0030574) and positive regulation of chemotaxis (GO:0050921) processes in OTSCC.

GO termentrzIDGene SymbolFold changeFDR level
GO:0030574
4312MMP157.60
4313MMP21.440.109
4314MMP38.431.01E-08
4316MMP72.830.0049
4317MMP81.010.7963
4318MMP94.085.85E-05
4319MMP108.459.95E-06
4320MMP112.020.00085
4322MMP133.790.0007
4325MMP160.930.1117
4327MMP191.080.4404
5184PEPD0.920.4602
5645PRSS20.760.0187
5653KLK60.730.4218
5657PRTN30.960.2656
9508ADAMTS31.050.5858
9509ADAMTS21.190.2451
56547MMP260.940.2394
GO:0050921
9353SLIT20.880.1700
566AZU10.950.1643
3576IL85.871.54E-06
6696SPP13.230.0027
7422VEGF1.200.4614
7857SCG21.000.9901
Expression values of the genes constitute of the altered biological processes in OTSCC. The altered biological processes in OTSCC were identified by Gene Ontology analysis (Table 2) as described in the Materials and Methods section. The expression values of the genes consisting of the altered biological processes were extracted from the RMA based expression index, and individual heat maps were generated for the identified altered biological processes in OTSCC. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting. To increase the contrast, values lower than the 10th percentile were replaced with the 10th percentile, and values higher than the 95th percentile were replaced with the 95th percentile. Expression values of genes that constitute the collagen catabolism (GO:0030574) and positive regulation of chemotaxis (GO:0050921) processes in OTSCC. Among these differentially expressed genes, some have potential value as diagnosis and prognosis markers, and may be indicative of their respective biological pathways. For example, IL8 is a prototypical chemokine (chemotactic cytokine) and is known for its involvements in the positive regulation of chemotaxis (GO:0050921), which is enhanced in tongue cancers as indicated by our Gene Ontology analysis. IL8 has also been suggested to be a potential biomarker for the early detection of oral cancer [16,17]. The over-expression of the MMP9 gene has been shown to be associated with progression of oral dysplasia to cancer [14]. Our recent study suggested that over-expression of the MMP9 gene is associated with advanced OTSCC and has predictive value for OTSCC lymph node metastasis [15]. The upregulation of MMP9 in OTSCC is also involved in the enhanced collagen catabolism (GO:0030574), as indicated by our Gene Ontology analysis. The qRT-PCR analyze were performed to validate the expressional differences of the IL8 and MMP9 genes between tongue SCCs and normal matching tissues. As shown in Figure 4A and 4B, the differences of both IL8 and MMP9 mRNA levels are statistically significant (p < .05) between OTSCC and normal tissues. The expression of MMP9 and IL8 was further confirmed by immunohistochemistry tests performed using monoclonal antibody to IL8 and MMP9 on 10 OTSCC cases (Figure 4C and 4D). Strong positive stained SCC cells were observed in 4 cases for IL8 and 8 cases for MMP9. The observation of positive staining of IL8 in OTSCC cells confirmed that SCC cells are one of the major sources of IL8 production at the site of oral cancer lesion.
Figure 4

Elevated expressions of IL8 and MMP9 genes in OTSCC. The qRT-PCR tests were performed with primer sets specific for IL8 gene (A) and MMP9 gene (B) on 25 OTSCC cases and 12 normal matching samples. The p values (Wilcoxon test) were presented. Immunohistochemistry tests were performed using monoclonal antibody to IL8 and MMP9 and detected using peroxidase-antiperoxidase and diaminebenzadine (DAB) on 10 OTSCC cases. Positive stained SCC cells were observed in 4 cases for IL8 and 8 cases for MMP9. Representative images for IL8 (C) and MMP9 (D) were presented.

Elevated expressions of IL8 and MMP9 genes in OTSCC. The qRT-PCR tests were performed with primer sets specific for IL8 gene (A) and MMP9 gene (B) on 25 OTSCC cases and 12 normal matching samples. The p values (Wilcoxon test) were presented. Immunohistochemistry tests were performed using monoclonal antibody to IL8 and MMP9 and detected using peroxidase-antiperoxidase and diaminebenzadine (DAB) on 10 OTSCC cases. Positive stained SCC cells were observed in 4 cases for IL8 and 8 cases for MMP9. Representative images for IL8 (C) and MMP9 (D) were presented.

Conclusion

The HNOSCCs are a diverse group of cancers, that develop from many different anatomic sites and are associated with different risk factors [1] and genetic characteristics [2]. This is the first high-resolution genomic profiling study to our knowledge that has focused on identifying unique expression patterns for tongue cancer (OTSCC). OTSCC is one of the most common types of HNOSCC, and is significantly more aggressive than other forms of HNOSCCs, with a propensity for rapid local invasion and spread [6]. Recent epidemiological studies suggested that the incidence of OTSCC is actually increasing in young and middle age groups [3-5]. In this study, we utilized a relatively large sample size (53 OTSCCs and 22 normal matching samples), which enabled us to capture a precise picture of the genome-wide expression pattern for this disease. It is possible that the genomic portrait of HNOSCC originating from different anatomic sites may be different. More studies will be needed to address this important question. In summary, we identified the unique expression pattern for OTSCC. Several interesting candidate genes associated with OTSCC were identified. The Gene Ontology analysis indicated that several biological processes and cellular functions are consistently altered in OTSCC. Our results demonstrate the feasibility of utilizing biomarkers discovered by global expression profiling analyses for the detection and diagnosis of OTSCC. In addition, we also provided a valuable reference dataset for future identification and validation of biomarkers for detection, diagnosis and prognosis of OTSCC.

Methods

Patients

Microarray data were generated from 26 microdissected OTSCC tissues and 12 matching normal tissue samples. Three additional microarray datasets from 27 OTSCC cases and 10 matching normal control tissues that published previously were either downloaded from GEO database (GSE2280, [46] and GSE3524, [47]) or requested from the authors [7]. Clinical characterizations of these patients are outlined in Table 4. The tumor stages were determined according to the American Joint Committee on Cancer (AJCC) designated classification. This study is approved by Institutional Review Boards at University of California at Los Angeles and at University of Illinois at Chicago.
Table 4

Clinical Characterization of the OTSCC Patients*

OTSCC (n = 53)Normal (n = 22)
AgeAverage5756
(Range)32–8237–78
GenderMale (%)73.659.1
Female (%)26.440.9
Anatomic SiteTongue (%)100100
Pathological T StageStage 4 (%)56.6
Stage 3 (%)7.5
Stage 2 (%)22.6
Stage 1 (%)13.2
Pathological N StageStage 2 (%)43.4
Stage 1 (%)7.5
Stage 0 (%)49.1

* The M stage data is not available.

Clinical Characterization of the OTSCC Patients* * The M stage data is not available.

Tumor procurement, RNA extraction and microarray hybridization

The OTSCC tissues and their matching normal samples were obtained for this study. These tissues were snap frozen. Cancer tissues containing more than 80% tumor cells based on haematoxylin and eosin (H&E) staining and pathological examination were identified and selectively microdissected by a trained pathologist. The total RNA was isolated using RNeasy Mini kit (Qiagen), and quantified by the RiboGreen RNA Quantitation Reagent (Molecular Probes). A total of 150–200 ng of purified total RNA was amplified by a modified T7 RNA amplification protocol as described previously [15,17]. The Enzo BioArray High Yield RNA Transcript Labeling System (Enzo) was used for labeling the sample prior to hybridization. The biotinylated cRNA (IVT product) was purified using the RNeasy kit (Qiagen). The quantity and purity of the biotinylated cRNA was determined by spectrophotometry and an aliquot of the sample was checked by gel electrophoresis. The samples were hybridized to the Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays according to the Affymetrix protocols. The arrays were scanned with a GeneChip Scanner 3000. The scanned array images were processed with GeneChip Operating software (GCOS), and the CEL files were extracted for further analysis.

Array data analysis and gene ontology analysis

The CEL files from all datasets (newly generated array data from 26 OTSCCs and 12 matching normals, and additional 27 OTSCCs and 10 normals from published studies [7,46,47]) were imported into the statistical software R 2.4.1 [48] using Bioconductor [49]. The meta-analysis was performed as described [50]. In brief, the Robust Multi-Array Average (RMA) expression measures [51] were computed after background correction and quantile normalization for each microarray dataset. Then, expression values of the overlapping probesets between U133A and U133 Plus 2.0 arrays were extracted. Probeset-level quantile normalization was performed across all samples to make the effect sizes similar among the four datasets. To visualize the overall expression patterns, we performed Principal Component Analysis (PCA) after removing the normal group mean vector separately from each of the four datasets. Finally, for every probeset, a mixed effects model was applied to identify differential expression. For gene i in sample k of experiment j, In the model, the random effect α is the laboratory effect, and β is the first-order cancer effect, which is our major focus in the identification of cancer-associated genes. After obtaining the estimates and the p-values of the β's of each probeset, we corrected the p-values for false discovery rate (FDR) [52]. We selected genes at the FDR level of 0.01, and with cancer effect size > 1 (> 2 fold change between cancer and normal samples). Functional analysis of the differentially expressed genes was carried out using the GOstats package in Bioconductor [22] based on the Gene Ontology Consortium database [23].

Quantitative RT-PCR(qRT-PCR)

The mRNA levels of interleukin-8 (IL8) and matrix metalloproteinases 9 (MMP9) in OTSCCs and normal tissues were further validated using qRT-PCR as previously described [15,17]. The RNA was converted to first strand cDNA using MuLV reverse transcriptase (Applied Biosystems) and the quantitative PCR was performed using iQ SYBR Green Supermix (Bio-Rad) in a BIO-RAD iCycler iQ real-time PCR detection system. The primer sets specific for IL8 (Forward: 5'-GAGGGTTGTGGAGAAGTTTTTG-3', Reverse: 5'-CTGGCATCTTCACTGATTCTTG-3') and for MMP9 (Forward: 5'-GCACGACGTCTTCCAGTACC-3', Reverse: 5'-TCAACTCACTCCGGGAACTC-3') were used. All reactions were performed in triplicate. The melting curve analyses were performed to ensure the specificity of the qRT-PCR reactions. The data analysis was performed using the 2-deltadelta Ct method described previously [53], where beta-actin was used as reference gene. The qRT-PCR based gene expression values between two groups were compared by the nonparametric Wilcoxon test.

Immunohistochemistry

The expression of IL8 and MMP9 in OTSCCs were further examined using immunohistochemistry tests as previously described [54]. In brief, the OTSCC tissues were processed, embedded, and sectioned at 5 μm. Tissue sections were stained using monoclonal antibody to IL8 (MAB208) (R & D Systems) and MMP9 (ab51203) (Abcam, Inc) and detected using peroxidase-antiperoxidase and diaminebenzadine (DAB) with a Discovery XT automated instrument (Ventana Medical Systems, Inc).

Authors' contributions

BZ, LM, DW, and XZ conceived the idea for the project and drafted the manuscript. HY, TY, ST, JS, JW and XZ performed the laboratory analyses and conducted statistical analyses. JS and JW provided discussions on clinical relevance. BZ, JS, JW, LM, DW and XZ revised the manuscript. All authors read and approved the final manuscript.

Additional file 1

Supplement Table S1: Up-regulated transcripts in OTSCC. The table showing the complete list of the up-regulated transcripts in OTSCC (p value < 0.01; fold increase > 2.0). Click here for file

Additional file 2

Supplement Table S2: Down-regulated transcripts in OTSCC. The table showing the complete list of the down-regulated transcripts in OTSCC (p value < 0.01; fold increase < 0.5). Click here for file

Additional file 3

Supplement Table S3: Enhanced Biological Processes (BP), Molecular Functions (MF) and Cellular Components (CC) in OTSCC. The table showing the complete list of the enhanced biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCC (p value < 0.01). Click here for file

Additional file 4

Supplement Table S4: Suppressed Biological Processes (BP), Molecular Functions (MF) and Cellular Components (CC) in OTSCC. The table showing the complete list of the suppressed biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCC (p value < 0.01). Click here for file

Additional file 5

Supplement Table S5: Expression values of genes that constitute the altered biological processes (listed in Table 2) in OTSCC. The table showing the statistics on expression values of genes that constitute the altered biological processes in OTSCC. Click here for file
  52 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Significance of immunohistochemical expression of manganese superoxide dismutase as a marker of malignant potential in colorectal carcinoma.

Authors:  Tadahiro Nozoe; Masayuki Honda; Sadaaki Inutsuka; Mitshuhiro Yasuda; Daisuke Korenaga
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

4.  MnSOD expression within tumor cells is closely related to mode of invasion in human gastric cancer.

Authors:  Daisuke Korenaga; Mitsuhiro Yasuda; Masayuki Honda; Tadahiro Nozoe; Sadaaki Inutsuka
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

5.  Dimension reduction and mixed-effects model for microarray meta-analysis of cancer.

Authors:  Tianwei Yu; Hui Ye; Zugen Chen; Barry L Ziober; Xiaofeng Zhou
Journal:  Front Biosci       Date:  2008-01-01

6.  Classification and identification of genes associated with oral cancer based on gene expression profiles. A preliminary study.

Authors:  Winston Patrick Kuo; Rifat Hasina; Lucila Ohno-Machado; Mark W Lingen
Journal:  N Y State Dent J       Date:  2003-02

7.  Transcriptional expression profiles of oral squamous cell carcinomas.

Authors:  Eduardo Méndez; Chun Cheng; D Gregory Farwell; Sherianne Ricks; S Nicholas Agoff; Neal D Futran; Ernest A Weymuller; Nicole C Maronian; Lue Ping Zhao; Chu Chen
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

8.  The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma.

Authors:  Joseph J Cullen; Christine Weydert; Marilyn M Hinkhouse; Justine Ritchie; Frederick E Domann; Douglas Spitz; Larry W Oberley
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

9.  Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults.

Authors:  Karin Annertz; Harald Anderson; Anders Biörklund; Torgil Möller; Saara Kantola; Jon Mork; Jörgen H Olsen; Johan Wennerberg
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

10.  Improved survival in the treatment of squamous carcinoma of the oral tongue.

Authors:  D Franceschi; R Gupta; R H Spiro; J P Shah
Journal:  Am J Surg       Date:  1993-10       Impact factor: 2.565

View more
  142 in total

1.  Co-expression of metalloproteinases 11 and 12 in cervical scrapes cells from cervical precursor lesions.

Authors:  Alejandra Valdivia; Raúl Peralta; Manuel Matute-González; Juan Manuel García Cebada; Ivonne Casasola; Cristina Jiménez-Medrano; Rogelio Aguado-Pérez; Vanessa Villegas; Cesar González-Bonilla; Leticia Manuel-Apolinar; Miguel Ibáñez; Mauricio Salcedo
Journal:  Int J Clin Exp Pathol       Date:  2011-10-12

2.  Genome-wide expression and copy number analysis identifies driver genes in gingivobuccal cancers.

Authors:  Srikant Ambatipudi; Moritz Gerstung; Manishkumar Pandey; Tanuja Samant; Asawari Patil; Shubhada Kane; Rajiv S Desai; Alejandro A Schäffer; Niko Beerenwinkel; Manoj B Mahimkar
Journal:  Genes Chromosomes Cancer       Date:  2011-11-10       Impact factor: 5.006

3.  Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma.

Authors:  Marni Stott-Miller; John R Houck; Pawadee Lohavanichbutr; Eduardo Méndez; Melissa P Upton; Neal D Futran; Stephen M Schwartz; Chu Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-29       Impact factor: 4.254

4.  Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma.

Authors:  Lu Jiang; Yang Dai; Xiqiang Liu; Cheng Wang; Anxun Wang; Zujian Chen; Caroline E Heidbreder; Antonia Kolokythas; Xiaofeng Zhou
Journal:  Hum Genet       Date:  2010-11-16       Impact factor: 4.132

5.  DEGAS: de novo discovery of dysregulated pathways in human diseases.

Authors:  Igor Ulitsky; Akshay Krishnamurthy; Richard M Karp; Ron Shamir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

6.  Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Authors:  David Maussang; Azra Mujić-Delić; Francis J Descamps; Catelijne Stortelers; Peter Vanlandschoot; Marijke Stigter-van Walsum; Henry F Vischer; Maarten van Roy; Maria Vosjan; Maria Gonzalez-Pajuelo; Guus A M S van Dongen; Pascal Merchiers; Philippe van Rompaey; Martine J Smit
Journal:  J Biol Chem       Date:  2013-08-26       Impact factor: 5.157

7.  Copy number changes of CRISP3 in oral squamous cell carcinoma.

Authors:  Wen-Chang Ko; Keisuke Sugahara; Takumi Sakuma; Ching-Yu Yen; Shyun-Yeu Liu; Gwo-An Liaw; Takahiko Shibahara
Journal:  Oncol Lett       Date:  2011-09-09       Impact factor: 2.967

Review 8.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 9.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

10.  Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.

Authors:  Lang-Ming Chi; Chien-Wei Lee; Kai-Ping Chang; Sheng-Po Hao; Hang-Mao Lee; Ying Liang; Chuen Hsueh; Chia-Jung Yu; I-Neng Lee; Yin-Ju Chang; Shih-Ying Lee; Yuan-Ming Yeh; Yu-Sun Chang; Kun-Yi Chien; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.